Precision Medicine Approaches for Developing Combination Therapies for the Treatment and Prevention of Alzheimer's Disease (AD) and AD-Related Dementias

Day 1, Monday, December 4

9:00 a.m. Welcome and Introductions, National Institute on Aging Program Staff

9:15 a.m. Plenary Talks

• Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Drug Development Landscape, Jeff Cummings, University of Nevada, Las Vegas
• Non-Pharrmacologic Interventions for AD/ADRD, Laura Baker, Wake Forest University
• Deconstructing Disease Complexity to Inform Development of Combination Therapies for AD/ADRD, Nathan Price, Thorne Health Tech

10:15 a.m. Break

10:30 a.m. Session 1 | Modeling Disease Complexity and Establishing Preclinical Proof-of-Concept for Combination Therapy Development, Chair: Marina Sirota, University of California, San Francisco

• Noam Beckmann, Icahn School of Medicine at Mt. Sinai
• Yaqiao Li, University of California, San Francisco
• Cynthia Lemere, Harvard University
• Eric Siemers, Acumen
• Q&A/ moderated discussion

12:00 p.m. Lunch Break

1:00 p.m. Session 2 | Systems-based Approaches to Understand the Mechanisms of Action and Responder Phenotypes for Pharmacologic and Non-Pharmacologic Interventions, Chair: Suzana Petanceska, National Institute on Aging

• Sid O'Bryant, University of North Texas Health Science Center
• Rima Kaddurah-Daouk, Duke University
• Mark Mapstone, University of California, Irvine
• Q&A/ moderated discussion

2:15 p.m. Session 3 | Considerations for Selecting Combination Interventions for Testing in Humans: What to Combine, When and for Whom, Chair: Reisa Sperling, Harvard University

• Frank Longo, Stanford University
• Suzanne Craft, Wake Forest University
• Roberta Diaz Brinton, University of Arizona
• Reisa Sperling, Harvard University
• Q&A/ moderated discussion

3:45 p.m. Break

4:00 p.m. Session 4 | Designing Clinical Trials for Testing Combination Therapies/Interventions, Chair: Laura Baker, Wake Forest University

• Rema Raman, University of Southern California
• Doris Molina-Henry, University of Southern California
• Kristine Yaffe, University of California, San Francisco
• Q&A/ moderated discussion

5:30 p.m. Adjourn Day 1

Day 2, Tuesday, December 5

9:30 a.m. Session 5 | Panel Discussion on Data and Biospecimen Sharing from Clinical Trials Moderator: Laurie Ryan, National Institute on Aging

• Discussants
• Laurie Ryan, National Institute on Aging
• Heather Snyder, Alzheimer's Association
• Sudhir Sivakumaran, Critical Path for Alzheimer's Disease

10:30 a.m. Session 6 | Regulatory Considerations for the Development of Combination Therapies for AD/ADRD, Teresa Buracchio, Food and Drug Administration

11:00 a.m. Session 7 | Moderated Discussion on Opportunities and Barriers for the Development of Combination Therapies for AD/ADRD

11:50 a.m. Closing remarks

12:00 p.m. Adjourn Day 2